本文關(guān)鍵詞：支架與藥物治療癥狀性顱內(nèi)動脈狹窄遠(yuǎn)期療效對比　出處：《介入放射學(xué)雜志》2016年02期 　論文類型：期刊論文

  更多相關(guān)文章： 癥狀性顱內(nèi)動脈狹窄 Wingspan支架 Solitaire支架 藥物

【摘要】：目的對比分析支架植入與藥物治療癥狀性中重度顱內(nèi)動脈狹窄的遠(yuǎn)期隨訪療效。方法采用回顧性研究、Kaplan-Meier法生存分析、Cox回歸模型等統(tǒng)計方法,對199例癥狀性中重度顱內(nèi)動脈狹窄患者經(jīng)支架植入與單純藥物治療的臨床資料進行對比分析,比較兩種治療方式的安全有效性及近、遠(yuǎn)期獲益差異。結(jié)果 Apollo、Wingspan、Solitaire支架植入成功率分別為100%、97.4%、98.5%,即刻殘余狹窄分別由術(shù)前(70.20±12.02)%、(78.61±12.15)%、(78.44±11.82)%下降至術(shù)后(18.00±6.33)%、(23.65±10.71)%、(17.21±8.02)%。支架植入組9例(8.5%)發(fā)生圍手術(shù)期并發(fā)癥,其中術(shù)中栓子脫落、穿支閉塞4例,急性血栓形成1例,血管迷走神經(jīng)反射2例,再灌注腦出血1例,術(shù)后第5天動脈-動脈栓塞事件1例。支架植入組與藥物治療組患者間主要終點事件發(fā)生率和累積發(fā)生率差異均無統(tǒng)計學(xué)意義(P=0.824,P=0.867)。結(jié)論 Solitaire支架和Wingspan支架植入治療癥狀性顱內(nèi)動脈狹窄均具有良好的安全有效性,遠(yuǎn)期獲益與藥物治療相比無顯著差異。
[Abstract]:Objective to compare the long-term follow-up results of stenting and drug therapy for symptomatic moderate and severe intracranial artery stenosis. Methods Kaplan-Meier survival analysis was performed retrospectively. The clinical data of 199 patients with symptomatic moderate and severe intracranial artery stenosis treated by stenting and drug therapy were analyzed by Cox regression model. Results the success rate of Apollo Wingspande Solitaire stent implantation was 100% respectively. 97.4% of the patients had immediate residual stenosis from 70.20 鹵12.02% to 78.61 鹵12.15%. 78.44 鹵11.82% decreased to 18.00 鹵6.33% and 23.65 鹵10.71%. The perioperative complications occurred in the stent implantation group (9 cases, 8.5%), in which the embolus fell off, perforating branch was occluded in 4 cases, and acute thrombosis occurred in 1 case. Two cases were vasovagal reflex and one case was cerebral hemorrhage after reperfusion. There was no significant difference in the incidence and cumulative incidence of major end point events between the stenting group and the drug treatment group on the 5th day after operation (P < 0. 824). Conclusion both Solitaire stents and Wingspan stents are safe and effective in the treatment of symptomatic intracranial artery stenosis. There was no significant difference in long-term benefits compared with drug therapy.
【作者單位】： 廣州中醫(yī)藥大學(xué);山東省臨沂市中醫(yī)醫(yī)院;廣東省中醫(yī)院腦病中心;
【分類號】：R743.3
【正文快照】： 顱內(nèi)動脈粥樣硬化性狹窄(ICAS)是缺血性卒中發(fā)病與復(fù)發(fā)的重要原因,其狹窄程度每提高10%,發(fā)生缺血性腦血管病的危險就增加26%[1]。ICAS患者各種原因所致年度卒中風(fēng)險為3.6%~13%[2-3],癥狀性ICAS患者卒中發(fā)病率及復(fù)發(fā)率更高[4-5]。因此,積極有效干預(yù)ICAS對降低卒中發(fā)病率、復(fù)發(fā)，

本文編號：1426880